Capecitabine: In advanced gastric or oesophagogastric cancer

Drugs

Volumn 67, Issue 4, 2007, Pages 601-610

  Dhillon, Sohita ^a   Scott, Lesley J ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; CYTIDINE DEAMINASE; CYTOTOXIC AGENT; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL; THYMIDINE PHOSPHORYLASE; UFT; WARFARIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ENZYME ACTIVITY; ESOPHAGUS CANCER; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INCIDENCE; INFECTION; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STOMACH CANCER; STOMATITIS; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; HUMANS; PRODRUGS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 33947301765     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767040-00010     Document Type: Review

References (29)

1. Khamly K, Jefford M, Michael M, et al. Recent developments in the systemic therapy of advanced gastroesophageal malignancies. Expert Opin Invest Drugs 2006; 15 (2): 131-53
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74-108
3. Leong T. Chemotherapy and radiotherapy in the management of gastric cancer. Curr Opin Gastroenterol 2005; 21 (6): 673-8
4. Macdonald JS. Gastric cancer: new therapeutic options. N Engl J Med 2006; 355 (1): 76-7
5. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 Suppl. 3: 49-58
6. Chong G, Cunningham D. Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial. Clin Oncol (R Coll Radiol) 2005; 17 (2): 79-80
7. Roche. New Xeloda combination allows patients with stomach cancer to live significantly longer [online]. Available from URL: http://www.prnewswire.co.uk [Accessed 2006 Jun 7]
8. Roche. Xeloda plus cisplatin combination effective in patients with advanced gastric cancer [online]. Available from URL: http://www.rocheusa.com [Accessed 2006 Aug 8]
9. McGavin JK, Goa KL. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 2001; 61 (15): 2309-26
10. Roche. Xeloda (capecitabine) tablets: US prescribing information [online]. Available from URL: http://www.fda.gov [Accessed 2006 Jun 7]
11. Roche. Xeloda (tablets): summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2006 Jun 7]
12. Robins GW, Keating GM. Capecitabine as adjuvant therapy in stage III colon cancer. Am J Cancer 2005; 4 (5): 315-23
13. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34 (8): 1274-81
14. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58 (4): 685-90
15. Kodera Y, Fujiwara M, Yokoyama H, et al. Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo 2005; 19 (5): 861-6
16. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40 (2): 85-104
17. Ramanathan RK, Ramalingam S, Egorin MJ, et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005; 55 (4): 354-60
18. Gollamudi R, Baker SD, Desai KK, et al. Pharmacokinetic (pk) and safety study of irinotecan (Ir) and capecitabine (Cp) administered on a weekly schedule [abstract no. 2061]. J Clin Oncol 2006; 24 Suppl. 18: 94
19. Evans TRJ, Pentheroudakis G, Paul J, et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophagogastric adenocarcinoma. Ann Oncol 2002; 13: 1469-78
20. Kang YK, Kang WK, Shin DB, et al. Randomized phase III trial of capecitabine/cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results [abstract no. LBA4018]. J Clin Oncol 2006; 24 Suppl. 18: 934. Plus oral presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
21. Cunningham D, Rao S, Starling N, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL 2 trial [abstract no. LBA4017]. J Clin Oncol 2006; 24 Suppl. 18: 934. Plus oral presentation at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
22. Moehler M, Kanzler S, Geissler M, et al. Irinotecan/ capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: interim analysis of a randomized German AIO phase II study [abstract no 4032]. J Clin Oncol 2006; 24 Suppl. 18: 186. Plus poster presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
23. Tebbutt N, Gebski V, Strickland A, et al. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer [abstract no. 4067]. J Clin Oncol 2006; 24 Suppl. 18: 194. Plus poster presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
24. Park Y, Lee J, Ryoo B, et al. A phase II study of capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with advanced gastric cancer [abstract no. 4079]. J Clin Oncol 2006; 24 Suppl. 18: 197. Plus poster presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)
25. Reyes S, Tellez E, Fernando A. Capecitabine and etoposide for patients with locally advanced or advanced gastric cancer: a Mexican Oncology Study Group phase II trial [abstract no. 1099P]. Ann Oncol 2006; 17 Suppl. 9: ix315. Plus poster presented at the 31st European Society of Medical Oncology Congress: 2006 Sep 29-30 Oct; Istanbul
26. Sakamoto J, Chin K, Kondo K, et al. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 2006; 17 (2): 231-6
27. Kang HJ, Chang HM, Kim TW, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005; 92 (2): 246-51
28. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92 (11): 1976-83
29. Park YH, Kim BS, Ryoo BY, et al. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006; 94 (7): 959-63